Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 21641952)

1.

Costs and impact of meningitis epidemics for the public health system in Burkina Faso.

Colombini A, Badolo O, Gessner BD, Jaillard P, Seini E, Da Silva A.

Vaccine. 2011 Jul 26;29(33):5474-80. doi: 10.1016/j.vaccine.2011.05.058. Epub 2011 Jun 12.

PMID:
21641952
2.

Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.

Miller MA, Wenger J, Rosenstein N, Perkins B.

Pediatr Infect Dis J. 1999 Dec;18(12):1051-9.

PMID:
10608623
3.

[Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].

da Silva A, Parent du Châtelet I, Beckr Gaye A, Dompnier JP, Seck I.

Sante. 2003 Oct-Dec;13(4):215-23. French.

PMID:
15047438
4.

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA.

Lancet Infect Dis. 2012 Oct;12(10):757-64. doi: 10.1016/S1473-3099(12)70168-8. Epub 2012 Jul 18.

PMID:
22818241
5.

Costs for households and community perception of meningitis epidemics in burkina faso.

Colombini A, Bationo F, Zongo S, Ouattara F, Badolo O, Jaillard P, Seini E, Gessner BD, Da Silva A.

Clin Infect Dis. 2009 Nov 15;49(10):1520-5. doi: 10.1086/644623. Review.

6.

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.

Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2008 Jan 1;46(1):1-13. doi: 10.1086/524041.

7.

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM.

Vaccine. 2012 May 30;30 Suppl 2:B40-5. doi: 10.1016/j.vaccine.2011.12.073. Review.

PMID:
22607898
8.

Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Dec 21;61(50):1022-4.

10.

Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.

Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team.

Pediatrics. 2005 May;115(5):1220-32.

PMID:
15867028
11.

Is hygiene promotion cost-effective? A case study in Burkina Faso.

Borghi J, Guinness L, Ouedraogo J, Curtis V.

Trop Med Int Health. 2002 Nov;7(11):960-9.

12.

Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing.

Parent du Châtelet I, Traore Y, Gessner BD, Antignac A, Naccro B, Njanpop-Lafourcade BM, Ouedraogo MS, Tiendrebeogo SR, Varon E, Taha MK.

Clin Infect Dis. 2005 Jan 1;40(1):17-25. Epub 2004 Dec 8.

13.

[An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].

Aplogan A, Batchassi E, Yakoua Y, Croisier A, Aleki A, Schlumberger M, Molina S, Sidatt M, Kaninda AV.

Sante. 1997 Nov-Dec;7(6):384-90. French.

PMID:
9503496
14.

Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso.

Decosas J, Koama JB.

Lancet Infect Dis. 2002 Dec;2(12):763-5.

PMID:
12467693
15.

Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.

LaForce FM, Okwo-Bele JM.

Health Aff (Millwood). 2011 Jun;30(6):1049-57. doi: 10.1377/hlthaff.2011.0328.

16.

Modeling the cost-effectiveness of the integrated disease surveillance and response (IDSR) system: meningitis in Burkina Faso.

Somda ZC, Perry HN, Messonnier NR, Djingarey MH, Ki SO, Meltzer MI.

PLoS One. 2010 Sep 28;5(9). pii: e13044. doi: 10.1371/journal.pone.0013044.

17.

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.

Mueller JE, Borrow R, Gessner BD.

Expert Rev Vaccines. 2006 Jun;5(3):319-36. Review.

PMID:
16827617
18.

Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study.

Tall H, Hugonnet S, Donnen P, Dramaix-Wilmet M, Kambou L, Drabo F, Mueller JE.

BMC Infect Dis. 2012 Jan 5;12:2. doi: 10.1186/1471-2334-12-2.

19.

Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.

Ouandaogo CR, Yaméogo TM, Diomandé FV, Sawadogo C, Ouédraogo B, Ouédraogo-Traoré R, Pezzoli L, Djingarey MH, Mbakuliyemo N, Zuber PL.

Vaccine. 2012 May 30;30 Suppl 2:B46-51. doi: 10.1016/j.vaccine.2011.12.112. Epub 2012 Jan 9.

PMID:
22230584
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk